Tags

Type your tag names separated by a space and hit enter

Induction and Kinetics of Complement-Fixing Antibodies Against Plasmodium vivax Merozoite Surface Protein 3α and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M.
J Infect Dis. 2019 11 06; 220(12):1950-1961.JI

Abstract

BACKGROUND

Complement-fixing antibodies are important mediators of protection against Plasmodium falciparum malaria. However, complement-fixing antibodies remain uncharacterized for Plasmodium vivax malaria. P. vivax merozoite surface protein 3α (PvMSP3α) is a target of acquired immunity and a potential vaccine candidate.

METHODS

Plasma from children and adults with P. vivax malaria in Sabah, Malaysia, were collected during acute infection, 7 and 28 days after drug treatment. Complement-fixing antibodies and immunoglobulin M and G (IgM and IgG), targeting 3 distinctive regions of PvMSP3α, were measured by means of enzyme-linked immunosorbent assay.

RESULTS

The seroprevalence of complement-fixing antibodies was highest against the PvMSP3α central region (77.6%). IgG1, IgG3, and IgM were significantly correlated with C1q fixation, and both purified IgG and IgM were capable of mediating C1q fixation to PvMSP3α. Complement-fixing antibody levels were similar between age groups, but IgM was predominant in children and IgG3 more prevalent in adults. Levels of functional antibodies increased after acute infection through 7 days after treatment but rapidly waned by day 28.

CONCLUSION

Our study demonstrates that PvMSP3α antibodies acquired during P. vivax infection can mediate complement fixation and shows the important influence of age in shaping these specific antibody responses. Further studies are warranted to understand the role of these functional antibodies in protective immunity against P. vivax malaria.

Authors+Show Affiliations

Menzies School of Health Research, Darwin, Australia. Charles Darwin University, Darwin, Australia.Research Centre for Infectious Diseases, School of Biological Sciences, University of Adelaide, Melbourne, Australia. Burnet Institute, Melbourne, Australia.Menzies School of Health Research, Darwin, Australia. Infectious Diseases Society Kota Kinabalu, Sabah-Menzies School of Health Research Clinical Research Unit, Queen Elizabeth Hospital, Kota Kinabalu, Malaysia. QIMR Berghofer Medical Research Institute, Brisbane, Australia.Infectious Diseases Society Kota Kinabalu, Sabah-Menzies School of Health Research Clinical Research Unit, Queen Elizabeth Hospital, Kota Kinabalu, Malaysia. Gleneagles Medical Centre, Kota Kinabalu, Malaysia.Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, Georgia.Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, Georgia. Division of Infectious Diseases, Department of Medicine, Emory University, Atlanta, Georgia.Burnet Institute, Melbourne, Australia. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia. Department of Infectious Diseases, Monash University, Melbourne, Australia. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. Department of Immunology and Pathology, Monash University, Melbourne, Australia.Menzies School of Health Research, Darwin, Australia. Infectious Diseases Society Kota Kinabalu, Sabah-Menzies School of Health Research Clinical Research Unit, Queen Elizabeth Hospital, Kota Kinabalu, Malaysia.Burnet Institute, Melbourne, Australia. Department of Microbiology, Monash University, Clayton, Australia. Department of Medicine, University of Melbourne, Parkville, Australia.Menzies School of Health Research, Darwin, Australia. Infectious Diseases Society Kota Kinabalu, Sabah-Menzies School of Health Research Clinical Research Unit, Queen Elizabeth Hospital, Kota Kinabalu, Malaysia.Menzies School of Health Research, Darwin, Australia. Burnet Institute, Melbourne, Australia. QIMR Berghofer Medical Research Institute, Brisbane, Australia.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

31419296

Citation

Oyong, Damian A., et al. "Induction and Kinetics of Complement-Fixing Antibodies Against Plasmodium Vivax Merozoite Surface Protein 3α and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M." The Journal of Infectious Diseases, vol. 220, no. 12, 2019, pp. 1950-1961.
Oyong DA, Wilson DW, Barber BE, et al. Induction and Kinetics of Complement-Fixing Antibodies Against Plasmodium vivax Merozoite Surface Protein 3α and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M. J Infect Dis. 2019;220(12):1950-1961.
Oyong, D. A., Wilson, D. W., Barber, B. E., William, T., Jiang, J., Galinski, M. R., Fowkes, F. J. I., Grigg, M. J., Beeson, J. G., Anstey, N. M., & Boyle, M. J. (2019). Induction and Kinetics of Complement-Fixing Antibodies Against Plasmodium vivax Merozoite Surface Protein 3α and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M. The Journal of Infectious Diseases, 220(12), 1950-1961. https://doi.org/10.1093/infdis/jiz407
Oyong DA, et al. Induction and Kinetics of Complement-Fixing Antibodies Against Plasmodium Vivax Merozoite Surface Protein 3α and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M. J Infect Dis. 2019 11 6;220(12):1950-1961. PubMed PMID: 31419296.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Induction and Kinetics of Complement-Fixing Antibodies Against Plasmodium vivax Merozoite Surface Protein 3α and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M. AU - Oyong,Damian A, AU - Wilson,Danny W, AU - Barber,Bridget E, AU - William,Timothy, AU - Jiang,Jianlin, AU - Galinski,Mary R, AU - Fowkes,Freya J I, AU - Grigg,Matthew J, AU - Beeson,James G, AU - Anstey,Nicholas M, AU - Boyle,Michelle J, PY - 2019/06/25/received PY - 2019/08/07/accepted PY - 2020/11/06/pmc-release PY - 2019/8/17/pubmed PY - 2020/5/23/medline PY - 2019/8/17/entrez KW - Plasmodium vivax KW - Complement-fixing antibodies KW - PvMSP3α KW - malaria SP - 1950 EP - 1961 JF - The Journal of infectious diseases JO - J. Infect. Dis. VL - 220 IS - 12 N2 - BACKGROUND: Complement-fixing antibodies are important mediators of protection against Plasmodium falciparum malaria. However, complement-fixing antibodies remain uncharacterized for Plasmodium vivax malaria. P. vivax merozoite surface protein 3α (PvMSP3α) is a target of acquired immunity and a potential vaccine candidate. METHODS: Plasma from children and adults with P. vivax malaria in Sabah, Malaysia, were collected during acute infection, 7 and 28 days after drug treatment. Complement-fixing antibodies and immunoglobulin M and G (IgM and IgG), targeting 3 distinctive regions of PvMSP3α, were measured by means of enzyme-linked immunosorbent assay. RESULTS: The seroprevalence of complement-fixing antibodies was highest against the PvMSP3α central region (77.6%). IgG1, IgG3, and IgM were significantly correlated with C1q fixation, and both purified IgG and IgM were capable of mediating C1q fixation to PvMSP3α. Complement-fixing antibody levels were similar between age groups, but IgM was predominant in children and IgG3 more prevalent in adults. Levels of functional antibodies increased after acute infection through 7 days after treatment but rapidly waned by day 28. CONCLUSION: Our study demonstrates that PvMSP3α antibodies acquired during P. vivax infection can mediate complement fixation and shows the important influence of age in shaping these specific antibody responses. Further studies are warranted to understand the role of these functional antibodies in protective immunity against P. vivax malaria. SN - 1537-6613 UR - https://www.unboundmedicine.com/medline/citation/31419296/Induction_and_kinetics_of_complement-fixing_antibodies_against_Plasmodium_vivax_MSP3α_and_relationship_with_IgG_subclasses_and_IgM L2 - https://academic.oup.com/jid/article-lookup/doi/10.1093/infdis/jiz407 DB - PRIME DP - Unbound Medicine ER -